


bsm-41327R**[Primary Antibody]****BioSS**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn


400-901-9800

TJP1 | ZO-1 Recombinant Rabbit mAb**— DATASHEET —****Host:** Rabbit**Isotype:** IgG**Clonality:** Recombinant**CloneNo.:** 4F3**GeneID:** 7082**SWISS:** Q07157**Target:** TJP1 | ZO-1**Immunogen:** Recombinant human ZO-1 protein: 1467-1748/1748.**Purification:** affinity purified by Protein A**Concentration:** 1mg/ml**Storage:** 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.**Background:** This gene encodes a member of the membrane-associated guanylate kinase (MAGUK) family of proteins, and acts as a tight junction adaptor protein that also regulates adherens junctions. Tight junctions regulate the movement of ions and macromolecules between endothelial and epithelial cells. The multidomain structure of this scaffold protein, including a postsynaptic density 95/disc-large/zona occludens (PDZ) domain, a Src homology (SH3) domain, a guanylate kinase (GuK) domain and unique (U) motifs all help to co-ordinate binding of transmembrane proteins, cytosolic proteins, and F-actin, which are required for tight junction function. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Aug 2017]**Applications:** WB (1:500-2000)**IHC-P** (1:100-500)**IHC-F** (1:100-500)**IF** (1:100-500)**Flow-Cyt** (1:50-200)**Reactivity:** Human, Mouse, Rat**Predicted MW.:** 191 kDa**Observed MW.:** 240 kDa**Subcellular Location:** Cell membrane ,Cytoplasm**— VALIDATION IMAGES —**


25 ug total protein per lane of various lysates (see on figure) probed with ZO-1 monoclonal antibody, unconjugated (bsm-41327R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.



Paraformaldehyde-fixed, paraffin embedded Human Colon Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; The section was incubated with ZO-1 Monoclonal Antibody, Unconjugated (bsm-41327R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.



Paraformaldehyde-fixed, paraffin embedded Rat Spleen; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; The section was incubated with ZO-1 Monoclonal Antibody, Unconjugated (bsm-41327R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.



Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

The MCF-7 (H) cells were fixed with 4% PFA (10 min at r.t.) and then permeabilized with 90% ice-cold methanol for 20 min at -20°C, the cells then were incubated in 5%BSA to block non-specific protein-protein interactions (30 min at r.t.), followed by secondary antibody incubation for 40 min at room temperature. Primary Antibody (green): Rabbit Anti-ZO-1/TJP1 antibody (bsm-41327R): 1 µg/10⁶ cells; Isotype Control (orange): Rabbit IgG (bs-0295P). Blank control (black): PBS. Acquisition of 20,000 events was performed.

— SELECTED CITATIONS —

- **[IF=26.8]** Lei Liu. et al. A Universal Strategy for BBB Transport Mediated by an Inflammatory Receptor Antagonist for Neuroprotection in Ischemic Stroke. ADV MATER. 2025 Sep;;e10035 WB,IF ;Mouse. 40922536
- **[IF=17.1]** Lei Liu. et al. Myricetin Oligomer Triggers Multi-Receptor Mediated Penetration and Autophagic Restoration of Blood-Brain Barrier for Ischemic Stroke Treatment. ACS NANO. 2024;XXXX(XXX):XXX-XXX WB ;Mouse. 38533773
- **[IF=7]** Qianwen Zheng. et al. Camel milk endogenous peptides ameliorated hyperglycemia in high-fat diet-fed C57BL/6 J mice in association with modulation of gut microbiota and the IRS/Akt and JNK/p38 pathways. FOOD RES INT. 2025 Apr;;116471 WB ;Mouse. 40382047
- **[IF=5.3]** Xu Wenxiu. et al. Limonene alleviated ulcerative colitis via anti-inflammation, anti-oxidation and regulating intestinal microenvironment in vivo and in vitro. INFLAMMOPHARMACOLOGY. 2025 Sep;;1-19 IHC,IF ;Human,Mouse. 40986263
- **[IF=4.8]** Xuwen Mao. et al. Mechanistic study on the restoration of intestinal barrier integrity and alleviation of inflammatory bowel disease by rhynchophylline via the AhR-NR4A1 pathway. FRONT PHARMACOL. 2025 Sep;16: WB,IF ;Human,Mouse. 41031160